About Cancer Genetics
SOPHiA GENETICS is a health technology company that has built SOPHiA DDM™, an AI-driven platform for precision medicine that analyzes complex health data to provide actionable clinical insights. The platform serves healthcare providers, biopharma companies, and patients globally, focusing primarily on oncology and rare genetic disorders. SOPHiA DDM™ processes genomic, radiomic, and multimodal data through advanced AI algorithms that achieve 98-99% accuracy across multiple applications. The company's technology supports end-to-end workflows for solid tumors, blood cancers, hereditary cancers, liquid biopsy, and inherited disorders. With a network of over 990 healthcare institutions across 75+ countries, SOPHiA GENETICS has analyzed more than 2.5 million genomic profiles. The platform is designed to be accurate, rapid, and scalable, adhering to strict regulatory standards including HIPAA and GDPR. The company's diverse team from 28 countries includes significant scientific expertise, with 30% holding PhDs. SOPHiA GENETICS operates on a philosophy of 'data for good,' connecting institutions globally while ensuring customers retain full control of their data. The platform offers specialized solutions including SOPHiA DDM™ for Genomics, Radiomics, and Multimodal analysis, along with add-on modules like Alamut Visual Plus and OncoPortal Plus.
Mission & Story
Mission
Democratizing Data-Driven Medicine, Together
Founding Story
The company was co-founded by Dr. Jurgi Camblong, who hosts the company's 'Decoded' podcast. The founding story mentions turning 'a single question' into innovation, though specific founding details are not fully elaborated in the scraped content.
Clinical Focus
Medical conditions and clinical areas addressed by Cancer Genetics.
Who It Serves
Milestones & Awards
Recent Milestones
Partnership with Jessa Ziekenhuis announced at European Congress of Pathology. Laboratorio Barnafi-Krause went live on SOPHiA DDM™. Published collaboration results with UroCCR. Reached 2 million genomic profiles analyzed milestone. Launched SOPHiA DDM™ Enhanced Exome Solutions. Presented at ASCO 2024 and BiotechX USA 2025.
Key Partnerships
Social & Media
Company Details
- Headquarters
- Boston, MA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.